APA (7th ed.) Citation

Hassanzadeh Eskafi, A., Oghalaei, A., Mahboudi, F., Ghaderi, H., Behdani, M., Shoari, A., & Kazemi-Lomedasht, F. (2023). Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis. Immunopharmacology & Immunotoxicology, 45(2), 197. https://doi.org/10.1080/08923973.2022.2131571

Chicago Style (17th ed.) Citation

Hassanzadeh Eskafi, Ayda, Akbar Oghalaei, Fereidoun Mahboudi, Hajarsadat Ghaderi, Mahdi Behdani, Alireza Shoari, and Fatemeh Kazemi-Lomedasht. "Investigation of the Therapeutic Potential of Recombinant Bispecific Bivalent Anti-PD-L1/VEGF Nanobody in Inhibition of Angiogenesis." Immunopharmacology & Immunotoxicology 45, no. 2 (2023): 197. https://doi.org/10.1080/08923973.2022.2131571.

MLA (9th ed.) Citation

Hassanzadeh Eskafi, Ayda, et al. "Investigation of the Therapeutic Potential of Recombinant Bispecific Bivalent Anti-PD-L1/VEGF Nanobody in Inhibition of Angiogenesis." Immunopharmacology & Immunotoxicology, vol. 45, no. 2, 2023, p. 197, https://doi.org/10.1080/08923973.2022.2131571.